FDA rejects Biohaven\'s sublingual formulation of ALS drug riluzole httpwww.firstwordpharma.comnode1654104tsid28®ionid6axzz5uKLFDTUzÂ
FDA rejects Biohaven's sublingual formulation of ALS drug riluzole http://www.firstwordpharma.com/node/1654104?tsid=28®ion_id=6#axzz5uKLFDTUz …
More From BioPortfolio on "FDA rejects Biohaven's sublingual formulation of ALS drug riluzole http://www.firstwordpharma.com/node/1654104?tsid=28®ion_id=6#axzz5uKLFDTUz …"